Orforglipron Phase 3 Trials Show Efficacy in T2D Management

Current GLP-1 receptor agonists, while highly effective in T2D management and weight reduction, are predominantly administered via subcutaneous injection. This route of administration can be a barrier for some patients, impacting treatment initiation and long-term adherence. The development of an oral formulation that maintains comparable efficacy and safety profiles is therefore a significant area of research. Orforglipron, a non-peptide GLP-1 receptor agonist, has been investigated in Phase 3 clinical trials to assess its efficacy and safety in adults with T2D. These trials aimed to determine if an oral GLP-1 receptor agonist could provide similar benefits to existing injectable options while offering the convenience of oral dosing.

The Trial Design and Key Findings

The Phase 3 program for orforglipron included multiple trials, enrolling a diverse population of adults with T2D, including those treatment-naive and those inadequately controlled on existing therapies. Participants were randomised to receive various doses of oral orforglipron once daily or placebo. The primary endpoints typically focused on the change in HbA1c from baseline, with key secondary endpoints including change in body weight and the proportion of participants achieving specific HbA1c targets (e.g., <7.0%).

Across the Phase 3 trials, orforglipron demonstrated dose-dependent and statistically significant reductions in HbA1c. In one pivotal trial, patients receiving the highest dose of orforglipron achieved a mean reduction in HbA1c of up to 2.1% from baseline, compared to a mean reduction of 0.4% in the placebo group (p<0.001).¹ A substantial proportion of patients, up to 72%, achieved an HbA1c target of less than 7.0% with orforglipron, compared to 20% with placebo (p<0.001).¹

Beyond glycaemic control, orforglipron also led to significant reductions in body weight. Patients treated with orforglipron experienced mean body weight reductions of up to 10.1 kg (approximately 10.0% of baseline body weight) over the trial duration, compared to a mean reduction of 1.5 kg in the placebo group (p<0.001).² These weight loss effects were observed consistently across different doses and patient subgroups.

The safety profile of orforglipron was consistent with the known class effects of GLP-1 receptor agonists. The most frequently reported adverse events were gastrointestinal in nature, including nausea, diarrhoea, vomiting, and constipation. These events were generally mild to moderate in severity and transient, decreasing in incidence over time. Discontinuation rates due to adverse events were higher in the orforglipron groups compared to placebo but remained within acceptable limits for this class of medication. No new safety signals were identified.³

Limitations and Future Directions

While the Phase 3 data for orforglipron are promising, the long-term cardiovascular outcomes data are still pending. The trials typically had durations of 26 to 52 weeks, which is sufficient for assessing glycaemic and weight outcomes but not for definitive cardiovascular safety and efficacy. Further studies, including dedicated cardiovascular outcomes trials, will be necessary to fully characterise the long-term benefits and risks of orforglipron. Additionally, head-to-head comparisons with other oral or injectable GLP-1 receptor agonists could provide further clarity on its relative position within the treatment landscape. The potential for drug-drug interactions with other orally administered medications also warrants careful consideration in clinical practice.